Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies

Background: The release of pro-inflammatory cytokines, resulting in cytokine storm syndrome, contributes to the morbidity and mortality associated with COVID-19 disease. This study aimed to compare the effects of intravenous (IV) and subcutaneous (SC) tocilizumab, an IL-6 receptor antagonist, on res...

Description complète

Détails bibliographiques

Auteurs principaux:	Monica A. Kaminski, Subin Sunny, Khayala Balabayova, Avneet Kaur, Aanchal Gupta, Marie Abdallah, John Quale
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2020-12-01
Collection:	International Journal of Infectious Diseases
Sujets:	COVID-19 Cytokine storm Tocilizumab
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S1201971220321640
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!